The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma ; volume:15 ; number:1 ; day:18 ; month:4 ; year:2015 ; pages:1-7 ; date:12.2015
BMC cancer ; 15, Heft 1 (18.4.2015), 1-7, 12.2015
- Creator
-
Ho, Thai H.
- Contributor
-
Liu, Xian-De
Huang, Yanqing
Warneke, Carla L.
Johnson, Marcella M.
Hoang, Anh
Tamboli, Pheroze
Wang, Fen
Jonasch, Eric
SpringerLink (Online service)
- DOI
-
10.1186/s12885-015-1302-1
- URN
-
urn:nbn:de:1111-2016110618685
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ho, Thai H.
- Liu, Xian-De
- Huang, Yanqing
- Warneke, Carla L.
- Johnson, Marcella M.
- Hoang, Anh
- Tamboli, Pheroze
- Wang, Fen
- Jonasch, Eric
- SpringerLink (Online service)
Other Objects (12)
Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib
Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study
Management of Metastatic Renal Cell Carcinoma
Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report
Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan
Systemic therapy in metastatic renal cell carcinoma
Treatment Options in Metastatic Renal Cell Carcinoma
Severe paraneoplastic hypereosinophilia in metastatic renal cell carcinoma
Metastatic Renal Cell Carcinoma Presenting as Gastrointestinal Bleeding
Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib
Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study
Management of Metastatic Renal Cell Carcinoma
Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report
Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan
Systemic therapy in metastatic renal cell carcinoma
Treatment Options in Metastatic Renal Cell Carcinoma
Severe paraneoplastic hypereosinophilia in metastatic renal cell carcinoma
Metastatic Renal Cell Carcinoma Presenting as Gastrointestinal Bleeding
Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib
Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study
Management of Metastatic Renal Cell Carcinoma
Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report
Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan
Systemic therapy in metastatic renal cell carcinoma
Treatment Options in Metastatic Renal Cell Carcinoma
Severe paraneoplastic hypereosinophilia in metastatic renal cell carcinoma